In addition to conventional blood markers, such as ALP (HR 1.1; 95% CI, 1–1.2) and LDH (HR 1.2; 95% CI, 1–1.5), FDG-positive tumor volume (HR2.6; 95% CI, 1.4–4.8) and mean intensity of PSMA-avid metastases uptake (HR 0.89; 95% CI, 0.8–0.98) also demonstrated a prognostic significance for survival in mCRPC undergoing RLT, confirming that patients with low volumes of FGD-avid disease had a longer OS than other patients (6.1 vs. 9.6 months, p < 0.001). Here, FOLH1 is linked to neoplasm.